rheumatoid arthritis complicated by sjogren'
Conditions
Interventions
None listed
Sponsors
Division of Clinical Immunology, Major of Advanced Biochemical Applications, Graduate School of Comprehensive Human Science,University of Tsukuba Takayuki Sumida
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)20 years-old< 2)Rheumatoid arthritis patinets according to criteria of ACR1987 or ACR/EULAR2010 3)Sjogren's syndrome patients according to criteria of the 1999 Ministry of Health and Welfare 4)Patients with subjective sicca symptoms 5) Patients who give a full consent to this study
Exclusion criteria
Exclusion criteria: 1)contraindicated patients 2)patients over 75 years of age 3)Patients with a total leukocyte count of 3000/mm3 or less, 4)pregnant women or lactating mothers, women with child-bearing potential and patients wishing to become pregnant during this study 5)patients under 20 years of age 6)patients who had received any drugs for treatment of Sjogren's syndrome, including cevimeline hydrochloride hydrate, anetholtrithion, and pilocarpine hydrochloride within 4 weeks prior to the study treatment 7) patients with any concurrent serious disorders of the liver, kidney or hematopoietic organs 8) anti centromere antibody positive 9)Patients who are inadequate by investigator's decision.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission at year 1,defined as a SDAI of less than 3.3 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) CRP,ESR,RF 2) Saxon test 3) salivary glands MRI 4) Immunoglobulins, the anti-SS-A/Ro antibody, the anti-SSB/La antibody 5) Patients VAS 6) Joint Radiographic assessment 7) Joint Magnetic resonance imaging assessment 8) ultrasonography | — |
Countries
Japan
Contacts
Public ContactIsao Matsumoto
Graduate School of Comprehensive Human Science,University of Tsukuba Division of Clinical Immunology,Mejor of Advanced Biochemical Applications
Outcome results
None listed